Overview
EVAX market data
Price History
EVAX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.02 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.26 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.45 – $12.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $26.7 · P/B 1.77 · P/S 3.49.
Company news
Evaxion To Present 3-Yr Clinical Efficacy Data From Phase 2 Trial With Personalized Cancer Vaccine Candidate EVX-01 At ESMO Congress 2026Benzinga · Jul 17, 2026, 11:19 AM
Reported Sunday, Evaxion Presents New Preclinical Data Showing Multi-Component EVX-V1 Vaccine Pairs AI-Discovered Antigens With AI-Optimized Antigens To Target CMV From Multiple AnglesBenzinga · Jul 13, 2026, 6:08 AM
Evaxion Says AI-Immunology-Developed EVX-04 Shows Immune Activation And Targeted Cell-Killing In Preclinical Acute Myeloid Leukemia DataBenzinga · Jun 11, 2026, 6:58 AM